BioSpace News Archive

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2023 financial results on Tuesday, August 8thth, 2023, before the financial markets open.

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced participation in the following August investor conferences.

IntelGenx Corp. today announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in preparation for a planned multicentre, randomized, double-blind, placebo-controlled clinical study (the “Study”) to investigate the use of IntelGenx’s Montelukast VersaFilm ® for the treatment of Parkinsons Disease.

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Scientific Officer, Linda C. Burkly, Ph.D.

NeuroOne Medical Technologies Corporation announced today the pricing of an underwritten registered public offering of 5,250,000 shares of its common stock at a price of $1.00 per share.

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for OFEV (nintedanib), investigating a potential treatment for children and adolescents between 6 to 17 years old with fibrosing interstitial lung disease (ILD).

Harmony Biosciences selected the latest round of nonprofit organizations for its Patients at the Heart and Progress at the Heart awards, which provide funding toward interdisciplinary community initiatives that address complex challenges facing people living with sleep disorders and rare neurological diseases.

Researchers from Children’s Hospital of Philadelphia used electronic health record data from more than 200,000 pediatric patients to describe patterns of pediatric allergies across the United States, validating a population-level pattern of allergy development known as the “allergic march,” in which allergies first present as eczema, followed by food allergies, asthma, and environmental allergies.

The US Food and Drug Administration has cleared a Numares Health test, the AXINON® LDL-p Test System, as a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease.

RemeGen Co., Ltd. has announced that their Phase II clinical study of telitacicept for the treatment of Primary Sjögren’s Syndrome in adults has been published in top international medical journal Rheumatology.